Evaluation of novel drugs using fMRI in early-phase clinical trials: safety monitoring
Authors:
- 1 August 2010
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 15 (15-16) , 684-689
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A ‘BOLD’ experiment in defining the utility of fMRI in drug developmentNeuroImage, 2008
- Proposed Regulations for Enforcement of the Patient Safety and Quality Improvement Act of 2005Plastic Surgical Nursing, 2008
- Expectations of Benefit in Early-Phase Clinical Trials: Implications for Assessing the Adequacy of Informed ConsentMedical Decision Making, 2008
- High-Performance Teams for Current and Future Physician Leaders: An IntroductionJournal of Surgical Education, 2008
- Standards for medical devices in MRI: Present and futureJournal of Magnetic Resonance Imaging, 2007
- Using positron emission tomography to facilitate CNS drug developmentTrends in Pharmacological Sciences, 2006
- A role for fMRI in optimizing CNS drug developmentNature Reviews Drug Discovery, 2006
- Negative functional MRI response correlates with decreases in neuronal activity in monkey visual area V1Nature Neuroscience, 2006
- Are novel drugs more risky for patients than less novel drugs?Journal of Health Economics, 2004
- Interpreting the BOLD SignalAnnual Review of Physiology, 2004